tirzepatide eyes eye issues with FDA Approves First Drug For Treatment Of Thyroid Disease Use of Semaglutide and tirzepatide eye issues with tirzepatide Complications

Interestingly, a recent large database study presented at ENDO 2024 suggested that GLP-1s may actually reduce the risk of recurrent pancreatitis in people with obesity and type 2 diabetes compared with some other diabetes drugs

In previous clinical trials, semaglutide has demonstrated significant reductions in MACE, including CV-related death, non-fatal myocardial infarction, and non-fatal stroke [38,39,40, 42,43,44,45]

: #Emerging #GLP-1 developers are using #regional #partnerships to enter high-prevalence markets faster, without bearing full commercial or regulatory risk

would be a member of Trump's Cabinet and advise the president on public health matters